NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Iktos

Iktos

Private
ParisHealthcare & Life Scienceshttps://iktos.ai/

Last Round

Grant

Feb 20, 2025

Total Funding Raised

$22.02M

Company Overview

Iktos is a biotechnology company that utilizes artificial intelligence and robotics platforms to accelerate the drug discovery and development process.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Medical AI, ML Platforms, Biotechnology, Industrial Robotics

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Revenue Share

AI Layer

Application

Keywords

AI drug discoverygenerative AIsmall molecule discoveryde novo drug designdrug discovery platformcomputer-aided drug designCADDAI retrosynthesisin silico drug designautomated synthesislab automationdesign-make-test-analyzeDMTAdrug discovery SaaSpharma techdrug discovery servicessynthesis planningdrug discovery pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iktos Comparables

Compare Iktos with similar companies based on industry and business-model similarity.

Iktos comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TandemAI
86%
PostEra
84%
Aqemia
83%

Iktos Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 20, 2025
Series AMar 9, 2023
SeedJan 1, 2019
SeedJul 5, 2018

Key People

Founding team and executive leadership

Nicolas Do Huu

Founder, Chief Technology Officer

Founding Team

Fabien Guillemot

CFO

Executive Team

Iktos Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 13, 2026

    Multi-year agreement with Servier Group, potentially exceeding €1 billion.

  • Feb 20, 2025

    Secured $2.61M in grant funding.

Iktos Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Iktos Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Iktos's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range67
Year Founded2016
Last FundingFeb 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.